Core Viewpoint - The company plans to repurchase shares with a budget of 5 million to 10 million yuan, with a maximum repurchase price of 30 yuan per share, aimed at implementing equity incentives or employee stock ownership plans [1] Summary by Categories Share Repurchase Plan - The company intends to repurchase between 166,700 to 333,300 shares, which represents 0.04% to 0.08% of the total share capital [1] - The repurchase period is set for 12 months from the date of board approval, with funding sourced from the company's own funds [1] Stakeholder Commitment - The company's controlling shareholder, actual controller, and board members have no plans to reduce their holdings in the next 3 to 6 months [1]

证券代码：688105 证券简称：诺唯赞 公告编号：2025-026 南京诺唯赞生物科技股份有限公司 关于公司董事长兼总经理、实际控制人 提议回购公司股份的提示公告 （一）回购股份的种类及回购方式：以集中竞价交易方式回购公司已发行的 人民币普通股（A 股）。 （二）回购股份的用途：用于股权激励或员工持股计划。若公司未能在股份 回购实施结果暨股份变动公告日后 3 年内使用完毕已回购股份，尚未使用的已回 购股份将予以注销。如国家相关政策调整，则回购方案按调整后的政策实行。 （三）回购股份的期限：自公司董事会审议通过回购方案之日起 12 个月内。 （四）回购股份的价格：不超过人民币 30 元/股（含）。 （五）回购股份的资金总额：不低于人民币 500 万元（含），不超过人民币 1,000 万元（含）。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 南京诺唯赞生物科技股份有限公司（以下简称"公司"）于 2025 年 6 月 17 日收到公司董事长兼总经理、实际控制人曹林先生递交的《关于提议南京诺唯赞 生物科技股份有限公司回购公司 ...

诺唯赞公告，公司董事长兼总经理、实际控制人曹林提议以集中竞价交易方式回购公司股份，回购资金 总额为500万元-1000万元，回购价格不超过人民币30元/股，回购股份用于股权激励或员工持股计划。 若未能在回购实施结果暨股份变动公告日后3年内使用完毕，尚未使用的回购股份将予以注销。提议人 在提议前6个月内未买卖公司股份，并承诺在董事会上对回购议案投赞成票。 ...

Core Insights - The article highlights the rise of domestic biological reagents in China, which have historically relied on imports, as the industry undergoes significant transformation due to the growth of the pharmaceutical and health sectors [1][2] - Nanjing Novozan Biotechnology Co., Ltd. has established a self-controlled technology platform, overcoming key technical challenges in high-end enzymes and antibodies, thereby enhancing China's biopharmaceutical supply chain [1][2][3] Industry Overview - Biological reagents, including enzymes and antibodies, are essential for research and development in life sciences, diagnostics, and vaccine production, often referred to as the "chip" of life sciences [1] - The industry has seen a shift as domestic companies like Novozan gain ground against foreign competitors, particularly in high-end reagent markets [1][2] Company Development - Founded in 2012, Novozan began its journey to develop localized biological reagents, addressing issues such as high costs and long delivery times associated with imported products [2][3] - The company has achieved significant breakthroughs in key technologies, enabling it to produce a range of over 1,000 types of recombinant enzymes and 3,000 types of high-performance antigens and monoclonal antibodies [5][6] Product Innovation - Novozan successfully developed a domestic high-sensitivity troponin test for early diagnosis of myocardial infarction, which is priced at 60% of the imported equivalent and delivers results in just 8 minutes [3][4] - The company is focusing on Alzheimer's disease (AD) blood testing, with products already in use in over 100 top-tier hospitals and third-party testing institutions [5][6] Marketing Strategy - Novozan's marketing approach for AD testing emphasizes a comprehensive service ecosystem that integrates technology development, clinical application, and academic outreach, rather than just product sales [6][7] - The company aims to enhance public awareness of AD and provide tailored solutions to medical institutions, establishing strategic partnerships to create a complete diagnostic and treatment ecosystem [6][7] International Expansion - Novozan has begun exporting products, including NGS (Next Generation Sequencing) reagents, to international markets, marking a significant step in its global strategy [8][9] - The company has established warehouses in key regions such as North America, Europe, and Southeast Asia to improve delivery times, reducing the product delivery cycle from 40-50 days to as little as 3 days [10]

Market Overview - The Shanghai Composite Index closed at 3399.77 points, above the six-month moving average, with a gain of 0.43% [1] - The total trading volume of A-shares reached 13126.55 billion yuan [1] Stocks Breaking the Six-Month Moving Average - A total of 220 A-shares have surpassed the six-month moving average today [1] - Notable stocks with significant deviation rates include: - Qitian Technology: 8.76% deviation, closing price at 14.00 yuan, with a daily gain of 16.86% and turnover rate of 21.88% [1] - Haochen Medical: 8.62% deviation, closing price at 3.12 yuan, with a daily gain of 9.86% and turnover rate of 7.25% [1] - Guangyun Technology: 8.13% deviation, closing price at 14.22 yuan, with a daily gain of 9.89% and turnover rate of 6.59% [1] Additional Stocks with Minor Deviations - Stocks with smaller deviation rates that have just crossed the six-month moving average include: - CITIC Special Steel: minor deviation, closing price at 20.30 yuan, with a daily gain of 10.69% [1] - Nanda Optoelectronics: minor deviation, closing price at 36.44 yuan, with a daily gain of 9.99% [1] -沃尔核材: minor deviation, closing price at 25.41 yuan, with a daily gain of 11.75% [1]

Market Overview - The Shanghai Composite Index closed at 3393.26 points, above the six-month moving average, with a change of 0.23% [1] - The total trading volume of A-shares reached 838.618 billion yuan [1] Stocks Breaking Six-Month Moving Average - A total of 184 A-shares have surpassed the six-month moving average today [1] - Notable stocks with significant deviation rates include: - Qitian Technology: 11.69% deviation, closing price 14.38 yuan, with a daily increase of 20.03% and turnover rate of 15.50% [1] - Haochen Medical: 8.62% deviation, closing price 3.12 yuan, with a daily increase of 9.86% and turnover rate of 6.44% [1] - Jinyinhai: 7.58% deviation, closing price 21.00 yuan, with a daily increase of 9.66% and turnover rate of 6.43% [1] Additional Stocks with Deviation Rates - Other stocks with notable performance include: - Guangyun Technology: 7.45% deviation, closing price 14.13 yuan, with a daily increase of 9.20% and turnover rate of 4.78% [1] - Yaowang Technology: 5.93% deviation, closing price 7.12 yuan, with a daily increase of 7.88% and turnover rate of 13.64% [1] - Nuotai Biotech: 5.91% deviation, closing price 55.37 yuan, with a daily increase of 10.36% and turnover rate of 5.58% [1] Summary of Other Stocks - Additional stocks with lower deviation rates that have just crossed the six-month moving average include: - Guangdong Hongtu: just above the six-month line [1] - Xinhe Shares: just above the six-month line [1] - Songjing Shares: just above the six-month line [1]

Core Points - Nanjing Novogene Bioinformatics Technology Co., Ltd. has been awarded the 25th China Patent Excellence Award for its invention patent "A Taq DNA Polymerase Mutant Mut4 and Its Application" [1][2] - The award is a recognition of the company's technological innovation capabilities and intellectual property efforts, which will help enhance its core competitiveness and facilitate the transformation of research and development achievements [2] Patent Details - Patent Name: A Taq DNA Polymerase Mutant Mut4 and Its Application [2] - Patent Number: ZL202010980814.1 [2] - Patent Holder: Nanjing Novogene Bioinformatics Technology Co., Ltd. [2] Application and Impact - The patented technology is based on the company's core platform for protein directed evolution and modification, improving enzyme tolerance and amplification performance for high-concentration blood samples [2] - The technology has broad applications in high-throughput sequencing, food safety testing, animal inspection and quarantine, and medical diagnostic testing [2] - The award will not have a significant impact on the company's recent performance [2]

证券代码：688105 证券简称：诺唯赞 公告编号：2025-025 南京诺唯赞生物科技股份有限公司关于 自愿披露获得中国专利优秀奖的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 国家知识产权局于近日发布了《关于第二十五届中国专利奖授奖的决定》（国 知发运字〔2025〕20 号），南京诺唯赞生物科技股份有限公司（以下简称"公 司"）的发明专利"一种 Taq DNA 聚合酶突变体 Mut4 及其应用"荣获第二十五 届中国专利优秀奖，具体情况如下： 中国专利奖是由国家知识产权局与世界知识产权组织共同评选并授予的重要奖 项。该奖项旨在遴选创造质量优、运用效益好、保护能力强、管理水平佳的高价值 专利，以表彰在技术（设计）创新和经济社会发展中做出突出贡献的专利权人及发 明人（设计人），推动科技创新与产业创新深度融合，促进发展新质生产力。 专利名称：一种 Taq DNA 聚合酶突变体 Mut4 及其应用 专 利 号：ZL202010980814.1 专利权人：南京诺唯赞生物科技股份有限公司 该专利系基于公司蛋白质定向改造与进化 ...

Core Viewpoint - Nanjing Novogene Bioinformatics Technology Co., Ltd. has signed a strategic cooperation agreement with Jiangsu Nuotai Aosaino Biopharmaceutical Co., Ltd. to establish a joint venture focused on synthetic biology, aiming to enhance technological advancements and project collaboration in the field [1][2]. Agreement Signing Overview - The strategic cooperation agreement does not require approval from the company's board of directors or shareholders [2]. - The agreement does not constitute a related party transaction or a major asset restructuring [2]. - The specific investment scale and construction plan for the joint venture will be determined later, indicating uncertainty [1][2]. Parties Involved - Jiangsu Nuotai Aosaino Biopharmaceutical Co., Ltd. is a publicly listed company with a registered capital of 224.87 million yuan and was established in March 2009 [2][3]. - The company has total assets of approximately 507.80 million yuan and a net profit attributable to shareholders of 40.44 million yuan [3]. Joint Venture Details - The joint venture will be co-owned, with Nanjing Novogene holding 49% and Jiangsu Nuotai holding 51% [1][4]. - The project will be implemented in two phases, with the first phase focusing on the renovation and expansion of existing production capacities [4]. - The ultimate goal is to establish an annual production capacity of approximately 10 tons of raw materials and corresponding formulations [4]. Investment and Funding - The specific investment amount will be confirmed by both parties [4]. - Initial funding will come from self-owned funds, with potential project financing for the second phase [4]. Governance Structure - The joint venture will have a board of directors composed of three directors from Jiangsu Nuotai and two from Nanjing Novogene [5]. - The management team will include a general manager nominated by Jiangsu Nuotai and other key positions filled through mutual agreement [5][6]. Operational Management - The joint venture will operate independently, with both parties sharing operational risks and responsibilities [6]. - The agreement includes non-competition clauses and stipulates that both parties will support each other in their respective areas of expertise [6][7]. Impact on Company - This strategic cooperation is expected to enhance the company's core competitiveness in the synthetic biology sector and extend its industrial value chain [7]. - The establishment of the joint venture is subject to regulatory approval and is not expected to significantly impact the company's 2025 performance [7][8].

证券代码：688105 证券简称：诺唯赞 公告编号：2025-024 南京诺唯赞生物科技股份有限公司 关于自愿披露签订战略合作协议 暨拟设立合资公司的公告 1 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 南京诺唯赞生物科技股份有限公司（以下简称"公司"）与江苏诺泰澳 赛诺生物制药股份有限公司（以下简称"诺泰生物"）近日于南京市签署《合成 生物学合作项目战略合作协议》（以下简称"《战略合作协议》"或"协议"）， 以合成生物学技术平台为基础，结合有机合成、化学工艺等交叉技术，共同推进 双方在合成生物学领域的技术进步和项目合作。 公司拟与诺泰生物共同设立一家生物制药公司（以下简称"合资公司" 或"项目公司"，具体名称待定，以市场监督管理机关登记的最终名称为准）， 公司持股比例为 49%，诺泰生物持股比例为 51%，以此为平台开展后续合作与具 体业务工作。合作项目的具体投资规模、建设方案等事项将由双方另行约定并履 行内部审议程序，尚具有不确定性。 本次拟对外投资事项不构成关联交易，也不构成重大资产重组。 风险提 ...